AstraZeneca

AZN

Drug Manufacturers - General · Healthcare

Also trades as: AZN.ST · AZN.L

Price

$165.98

+1.49 (+0.91%)

Market Cap

$257.41B

Exchange

New York Stock Exchange

Winston Score

Winston is happy

A high-quality business with solid fundamentals.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Strong

Growth

Exceptional

Cash Flow

Exceptional

Stability

Strong

Valuation

Strong

Dividends

Mixed

Track this stock — start free trial

Share count rising — dilution

+9.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 1.43B (2021) → 1.56B (2025)

Winston Score History

The full picture

AstraZeneca is a global pharmaceutical company that discovers, makes, and sells prescription medicines. Its main products include cancer drugs like Tagrisso and Enhertu, heart and kidney medicines like Farxiga, and respiratory treatments like Symbicort. It sells primarily to hospitals, clinics, and pharmacies, with patients and healthcare systems as the end users.

The company earns money by selling branded prescription drugs, which carry high prices protected by patents. AstraZeneca operates in over 100 countries, with major revenue coming from the US, Europe, and a fast-growing China business. Its competitive edge comes from a strong oncology pipeline and deep research partnerships, but patent expirations on key drugs remain a persistent risk — when patents expire, cheaper generic versions can quickly erode sales. The company's ability to keep launching new cancer and rare-disease treatments from its pipeline will be the main factor driving future growth.

Politician Trades

12 trades / 12mo

8 Congressional buys and 4 sells on AZN in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+5.1% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+1.3% YoY

YoY Growth Rate

Slow EPS growth

R&D Spend

$14.2B/ year

→ Flat (+5% vs prior year)

24.2% of revenue

In line with sector average (18%)

Steady R&D investment year-over-year

Insider Activity

0.4%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$9.6B cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

AstraZeneca is growing revenue at 5% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

73.6%

Premium pricing power — 73.6% gross margin

Profit after running costs

Operating Margin

20.2%

Excellent — 20.2% operating margin

Return on the money invested

ROCE

17.3%

Strong — 17.3% return on capital

ROIC between 15% and 25%. Every dollar invested in the business earns 15 to 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+8.3%

Steady sales growth (+8.3% YoY)

Profit growth

EPS YoY

+25.8%

Earnings growing fast (+25.8% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is

EPS Consistency

8/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

133%

Turns 133% of profit into real cash

Spare cash per sale

FCF Margin

14.3%

Converts sales into free cash efficiently (14.3%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.59

Conservative — low debt load (0.59)

Covers its interest

Interest Cover

8.03x

Comfortably covers interest (8.0x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

24.9x

Growth-priced — P/E 24.9

P/E above the market average. People are paying up for expected growth.

Cheaper or dearer next year

P/E vs Forward

+11.6

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (24.9 → 13.3)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

1.87%

Small dividend — 1.87% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend record

Dividend Growth

+8.9%

Dividend growing modestly (8.9% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial